Management holds a KOL conference call to discuss interim data from the Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD) on December 6 at 2 pm. Webcast Link
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LUMO:
- Lumos Pharma to host conference call
- Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
- Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Piper ‘not concerned’ about two outliers in Lumos’ OraGrowtH210 rhGH cohort
- Lumos Pharma downgraded to Hold from Buy at Jefferies